Brokerage Firm Rating on Astrazeneca PLC (AZN)

Astrazeneca PLC (AZN) : 4 analysts are covering Astrazeneca PLC (AZN) and their average rating on the stock is 2.5, which is read as a Buy. 1 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels. A total of 3 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.

Astrazeneca PLC (AZN) has been rated by 3 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $38 and the lowest price target forecast is $35. The average forecast of all the analysts is $36.17 and the expected standard deviation is $1.26.


Company shares have received an average consensus rating of Hold for the current week Astrazeneca PLC (NYSE:AZN): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $33.69 and $33.61 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $33.97. The buying momentum continued till the end and the stock did not give up its gains. It closed at $33.81, notching a gain of 0.77% for the day. The total traded volume was 3,568,075 . The stock had closed at $33.55 on the previous day.

AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. The Company discovers, develops and commercializes prescription medicines for cardiovascular and metabolic diseases; oncology; respiratory, inflammation and autoimmunity, and infection, neuroscience and gastrointestinal. Its medicines include Crestor for managing cholesterol levels; Seloken/Toprol-XL for hypertension, heart failure and angina; Iressa for lung cancer; Faslodex for breast cancer; Zoladex for prostate and breast cancer; Nexium for acid-related diseases; Seroquel XR for schizophrenia, bipolar disorder and depressive disorder, and Synagis for RSV (respiratory syncytial virus), a respiratory infection in infants. It also offers potassium-binding compound sodium zirconium cyclosilicate (ZS-9), a treatment for hyperkalaemia, a condition associated with increased mortality in patients with chronic kidney disease (CKD), diabetes mellitus (DM) and chronic heart failure (CHF).

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.